Your browser doesn't support javascript.
loading
Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case-Control Study.
Jodal, Henriette C; Akwiwu, Eddymurphy U; Lemmens, Margriet; Delis-van Diemen, Pien M; Klotz, Dagmar; Leon, Leticia G; Lakbir, Soufyan; de Wit, Meike; Fijneman, Remond J A; van Leerdam, Monique E; Dekker, Evelien; Spaander, Manon C W; Meijer, Gerrit A; Løberg, Magnus; Coupé, Veerle M H; Kalager, Mette; Carvalho, Beatriz.
Afiliación
  • Jodal HC; Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
  • Akwiwu EU; Clinical Effectiveness Research Group, Oslo University Hospital, Oslo, Norway.
  • Lemmens M; Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
  • Delis-van Diemen PM; Department of Epidemiology and Data Science, Amsterdam Public Health Research Group, Amsterdam University Medical Centers, Location VU Medical Center, Amsterdam, the Netherlands.
  • Klotz D; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Leon LG; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Lakbir S; Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
  • de Wit M; Department of Pathology, Oslo University Hospital, Oslo, Norway.
  • Fijneman RJA; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van Leerdam ME; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Dekker E; Bioinformatics Group, Department of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Spaander MCW; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Meijer GA; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Løberg M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Coupé VMH; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Kalager M; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, the Netherlands.
  • Carvalho B; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Cancer Res Commun ; 3(11): 2292-2301, 2023 11 13.
Article en En | MEDLINE | ID: mdl-37921412
ABSTRACT
Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may result in suboptimal surveillance. Certain DNA copy-number alterations (CNAs) are associated with adenoma-to-carcinoma progression. We aimed to evaluate whether these molecular features can better predict an individual's risk of me-CRC than the morphologic advanced adenoma features.In this nested case-control study, 529 individuals with a single adenoma at first colonoscopy were selected from a Norwegian adenoma cohort. DNA copy-number profiles were determined, by low-coverage whole-genome sequencing. Prevalence of CNAs in advanced and non-advanced adenomas and its association (OR) with me-CRC was assessed. For the latter, cases (with me-CRC) were matched to controls (without me-CRC) on follow-up, age and sex.CNAs associated with adenoma-to-carcinoma progression were observed in 85/267 (32%) of advanced adenomas and in 27/262 (10%) of non-advanced adenomas. me-CRC was statistically significantly associated, also after adjustment for other variables, with age at baseline [OR, 1.14; 95% confidence interval CI), 1.03-1.26; P = 0.012], advanced adenomas (OR, 2.46; 95% CI, 1.50-4.01; P < 0.001) and with the presence of ≥3 DNA copy-number losses (OR, 1.90; 95% CI. 1.02-3.54; P = 0.043).Molecularly-defined high-risk adenomas were associated with me-CRC, but the association of advanced adenoma with me-CRC was stronger.

SIGNIFICANCE:

Identifying new biomarkers may improve prediction of me-CRC for individuals with adenomas and optimize surveillance intervals to reduce risk of colorectal cancer and reduce oversurveillance of patients with low risk of colorectal cancer. Use of DNA CNAs alone does not improve prediction of me-CRC. Further research to improve risk classification is required.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma / Neoplasias Colorrectales / Adenoma Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2023 Tipo del documento: Article País de afiliación: Noruega

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma / Neoplasias Colorrectales / Adenoma Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2023 Tipo del documento: Article País de afiliación: Noruega